Meet the LBCTrialists (non-ACE)-Meet the LBCTrialists (non-ACE)

Video Transcription

Video Summary

The session, "Meet the Trialists," facilitated a Q&A with primary investigators (PIs) of several clinical trials after presenting their trial overviews, moderated by Dr. Sana Al-Khatib from Duke University. Dr. Frederic Sacher discussed the "in-your-heart" study evaluating CT-guided ablation for ventricular tachycardia, showing reduced procedural duration and costs yet highlighting potential for further improvements through imaging enhancements and new ablation tools. The session highlighted the importance of increasing female representation in trials as currently male participants dominate due to historical incidences of myocardial infarctions in men.<br /><br />Dr. Varun Sundaram shared findings from the TRANSFORM-AF trial on using GLP-1 receptor agonists for secondary atrial fibrillation prevention, particularly beneficial for obese patients with diabetes. The study showed a 13% reduction in AF-related incidents with these therapeutics, indicating their potential despite current high costs and acknowledging the challenge in conducting randomized controlled trials due to ethical reasons.<br /><br />Dr. Derek Chu covered the MAPIT CRT trial about MRI model-based versus standard lead placements in CRT devices, resulting in improved ejection fraction outcomes in the former group. The trial faced slow enrollment, spotlighting challenges like technology availability and evolving practices like conduction system pacing.<br /><br />Dr. Arwa Yunus presented an analysis from the OPTION trial focusing on AFib outcomes post-Watchman device implantation during AFib ablation, revealing no significant difference in arrhythmia recurrence, albeit concerns remain about post-procedural management of AFib recurrences in the presence of such devices.<br /><br />Finally, Dr. Alexandre Almorad and Dr. Vivek Reddy presented innovations in catheter technology for PVI procedures in atrial fibrillation treatment. Dr. Reddy highlighted the safety and efficacy of a new catheter system from the PulseR trial, suggesting its promising role in reducing procedural complexities and ensuring high safety standards, though future adoption may face challenges relating to training requirements and costs. <br /><br />Discussion addressed safety profiles, procedural efficiencies, and application potentials in clinical practice, underlining the ongoing evolution in electrophysiological interventions.

Keywords

clinical trials

ventricular tachycardia

atrial fibrillation

GLP-1 receptor agonists

CT-guided ablation

female representation

MRI model-based CRT

Watchman device

catheter technology

electrophysiological interventions